Trials / Completed
CompletedNCT00488306
Study Evaluating the Safety and Efficacy of Tigecycline in Hospitalized Patients With cIAI
A Multicenter, Open Label Study to Evaluate the Efficacy and Safety of Tigecycline to Treat Complicated Intra-Abdominal Infections (cIAI) in Hospitalized Patients
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In light of tigecycline's activity against these resistant bacteria, tigecycline may represent a viable new therapy for complicated intra-abdominal infections.
Detailed description
To evaluate the efficacy and safety of tigecycline to treat complicated intra-abdominal infections in hospitalized patients. Both the clinical response profile and the microbiological response profile will be assessed. The primary endpoint will be clinical response within the microbiological evaluable population at the test-of-cure assessment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | tigecycline |
Timeline
- Start date
- 2006-08-01
- Completion
- 2007-08-01
- First posted
- 2007-06-20
- Last updated
- 2009-07-07
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT00488306. Inclusion in this directory is not an endorsement.